Equal Treatment Means Equal Survival for African-Americans With Prostate Cancer

Publication
Article
OncologyONCOLOGY Vol 9 No 6
Volume 9
Issue 6

African-American men with prostate cancer live as long as their white counterparts if they receive the same treatment, two cancer research studies show. African-American men, however, are not receiving comparable treatment, says Dr. Mack

African-American men with prostate cancer live as long as theirwhite counterparts if they receive the same treatment, two cancerresearch studies show. African-American men, however, are notreceiving comparable treatment, says Dr. Mack Roach, AssistantProfessor of Radiation Oncology and Medical Oncology at the Universityof California, San Francisco. They also aren't going to the doctoruntil they have late-stage disease, he notes. These are the mainreasons why African-Americans are two times more likely to dieof the disease than white men, he says.

Some people have suggested that just because a person is African-Americanhis cancer will be more deadly, says Dr. Roach. "This issimply not true," he contends.

Some studies have reported that, overall, African- American mendo worse than their white counterparts. When African-Americanmen took part in studies conducted by the Radiation Therapy OncologyGroup (RTOG) this wasn't the case, Dr. Roach reports. The studiesoffered quality standardized care, according to Dr. Roach.

African-American men diagnosed with prostate cancer should asktheir doctor if they can participate in a cancer research study,advises Dr. Jim Cox, Chairman of the RTOG. These studies guaranteethat all patients, regardless of race, receive the same treatmentas other men in the studies.

"Quality care is essential, but African-Americans also mustget screened early if we want to reduce the number of prostatecancer deaths in this group," says Dr. Roach. This is exactlythe opposite of what is happening, he says. Perhaps because ofgreater access and heightened awareness, more whites are beingscreened. "The difference in stage of disease at diagnosisbetween African- Americans and whites is getting larger,"notes Dr. Roach.

Recent Videos
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Biochemical markers and advanced imaging modalities play a critical role in monitoring patients undergoing RLT therapy for metastatic prostate cancer.
Data support the use of radioligand therapy in combination with androgen receptor pathway inhibitors to optimize prostate cancer outcomes.
Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Related Content